Clinical Trials on Hepatitis C (HCV)

Total 14481 results

National Institutes of Health Clinical Center (CC)

Completed

Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia

HCV HIV

United States
University of California, Irvine
University of California, Los Angeles; National Institute on Minority Health...

Completed

Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults

Hepatitis C Virus (HCV) Infection

United States
University of Valencia
Hoffmann-La Roche

Unknown

Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV

Chronic Hepatitis C | Co-Infection HIV-HCV

Spain
Alios Biopharma Inc.
Janssen Pharmaceutica

Terminated

First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C

Chronic Hepatitits C

Georgia, Moldova, Republic of, France
AbbVie

Completed

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
AbbVie (prior sponsor, Abbott)

Completed

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Chronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)

United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
AbbVie

Completed

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Chronic Hepatitis C Virus (HCV)
AbbVie (prior sponsor, Abbott)

Completed

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Hepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1

United States
AbbVie

Completed

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
AbbVie (prior sponsor, Abbott)

Completed

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 (Champion2)

Hepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1

United States, Puerto Rico
Trek Therapeutics, PBC

Completed

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Chronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral Infection

United States, New Zealand
Trek Therapeutics, PBC

Completed

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral Infection

United States
University College London Hospitals

Completed

Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication

Chronic Hepatitis C, HCV Genotype 1

United Kingdom
University of Cincinnati
Merck Sharp & Dohme LLC

Completed

The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients

Hepatitis C, Chronic | HIV | HCV Coinfection

United States
AbbVie

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (DORA)

Hepatitis C Virus (HCV)

United States, Belgium, Canada, Germany, Japan, Puerto Rico, Russian Federation, Spain, United Kingdom
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

Hepatitis C Virus (HCV)

Brazil
AbbVie

Completed

ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C Virus (HCV)
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

HCV

China
Fundacion SEIMC-GESIDA

Withdrawn

A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A (C-RESCUE)

HCV

Spain
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)

Hepatitis C Virus (HCV) Infection

France
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)

Chronic Hepatitis C | Hepatitis C Virus | HCV
AbbVie

Completed

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)

Hepatitis C Virus (HCV)
AbbVie

Completed

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (ENDURANCE-5 6)

Hepatitis C Virus (HCV)

United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
AbbVie

Completed

A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation (DETI-2)

Hepatitis C Virus (HCV)

Russian Federation
Merck Sharp & Dohme LLC

Completed

Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects

Chronic Hepatitis C (HCV)
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation (REPLACE)

Chronic Hepatitis C Virus (HCV) Infection

France, United Kingdom, Spain, Germany, Belgium, Austria
HaEmek Medical Center, Israel
AbbVie

Completed

Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B

HCV Coinfection

Israel
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Chronic Hepatitis C

New Zealand
Hadassah Medical Organization

Withdrawn

Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy

Asymptomatic Chronic HCV Carriers

Israel
Hoffmann-La Roche

Completed

Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

HCV

Puerto Rico, United States
Asociacion para el Estudio del Higado
Merck Sharp & Dohme LLC

Unknown

Chronic Hepatitis C in Chronic Hemodialysis Recipients - An Observational Study ((CHINCHERO))

HCV Infection
AbbVie

Recruiting

A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus

Hepatitis C Virus (HCV)

Japan
AbbVie

Completed

Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response (CHOICE)

Hepatitis C Virus (HCV)

Russian Federation
AbbVie

Completed

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis (EXPEDITION-8)

Hepatitis C Virus (HCV)

United States, Bulgaria, Canada, Czechia, France, Greece, Hungary, Ireland, Israel, Italy, Poland, Portugal, Puerto Rico, Romania, Russian Federation, Spain, Taiwan, United Kingdom, Vietnam
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment (EXPEDITION-5)

Hepatitis C Virus (HCV)

United States, Canada, Germany, Greece, Italy, Korea, Republic of, Poland, Puerto Rico, Spain, Sweden
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Chronic Hepatitis C | Hepatitis C Virus (HCV) Infection

United States, Puerto Rico
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4)

Chronic Hepatitis C Virus (HCV) Infection
AbbVie

Completed

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults

Chronic Hepatitis C Virus (HCV Infection Genotype 1)
Gilead Sciences

Completed

Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice

HCV Infection

Mexico
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection (ENDURANCE-2)

Chronic Hepatitis C Virus (HCV) Infection
University Hospital, Strasbourg, France

Unknown

Clinical Investigation of Erlotinib as an HCV Entry Inhibitor

Chronic Hepatitis C Infection | HCV Genotype 1b

France
Atea Pharmaceuticals, Inc.

Withdrawn

Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

Hepatitis C Virus Infection | Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C | HCV Infection

Belgium
Atea Pharmaceuticals, Inc.

Completed

Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection | Hepatitis C | Hepatitis C, Chronic | Chronic Hepatitis C | HCV Infection

Belgium, Mauritius, Moldova, Republic of
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

Chronic HCV Infection

United States
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

Chronic Hepatitis C | Hepatitis C Virus | HCV
Alexion Pharmaceuticals
Achillion, a wholly owned subsidiary of Alexion

Terminated

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

HCV Infection

United States, Germany, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Hepatitis C | Chronic Hepatitis C | HCV | CHC

New Zealand
AbbVie

Completed

Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis (EASY)

Hepatitis C Virus (HCV)

Russian Federation
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

United States

3

Subscribe